Focus:
Comment
-
16 September 2019
Chasing Cancer considers how to improve patient access to cancer therapies
The discussion was focused on the decreasing involvement of patient participation in clinical trials and mitigation efforts taken by cancer research institutes and pharmaceutical companies.
-
6 September 2019
ESC updates first-line treatment guidelines for type 2 diabetics with cardiovascular disease
The ESC’s updated guidelines are an important step forward in addressing CV risk, which has historically remained an unresolved issue in patients living with diabetes.
-
5 September 2019
Traffic to top type 2 diabetes websites tends to spike when major cardiovascular outcomes studies are presented
Visits to the Eli Lilly’s Trulicity (dulaglutide) brand site spiked massively in June 2019, bringing it to the top position by a landslide, despite a lack of digital display advertising...
-
29 August 2019
Oklahoma wins landmark suit against J&J for role in opioid crisis
In a landmark ruling, Oklahoma has become the first US state to successfully sue a pharmaceutical company for its contribution to the opioid addiction crisis.
-
29 August 2019
US sees increase in severe Pulmonary disease, likely linked to E-cigarettes
The US Centers for Disease Control and Prevention recently issued a press release reporting a rise in severe lung illness associated with e-cigarette use.
-
29 August 2019
Resurrection of Fedratinib results in FDA approval for Myelofibrosis
On August 16, the FDA approved Celgene’s second-generation JAK2 kinase inhibitor. The therapy, titled Inrebic (fedratinib), is for intermediate-2 or high-risk forms of myelofibrosis.
-
29 August 2019
The current clinical trial space for Tuberculosis
On August 14, TB Alliance became the first nonprofit organisation to receive FDA regulatory approval for its drug, pretomanid, for the treatment of tuberculosis.
-
29 August 2019
Glenmark wins regulatory approval to market diabetes drug in India
Glenmark Pharmaceuticals has achieved regulatory approval in India for its novel type 2 diabetes (T2D) combinatorial drug. The therapy consists of remogliflozin etabonate—a sodium-glucose cotransporter-2 (SGLT-2) inhibitor—and metformin hydrochloride.
-
29 August 2019
AZ versus GSK: the battle in front-line treatment of ovarian cancer
AstraZeneca and its partner, Merck & Co., have strengthened their position in ovarian cancer for their poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor. In aPhase III PAOLA-1, the therapy,...
-
28 August 2019
AbbVie scores FDA approval for RA therapy amid safety concerns
AbbVie has received FDA approval in rheumatoid arthritis (RA) for its JAK-1 inhibitor upadacitinib. The therapy is set to be marketed as Rinvoq, with a recommended dose of 15mg once...
Go Top
